Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
DYDyadic International, Inc. logo

Dyadic International, Inc. (DYAI)

NASDAQ Capital Market · Currency in USD
$0.40 ▼ 0.00 (-0.75%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.41 ▲ +0.01 (+2.88%)
After hours: Oct 23, 7:17 PM ET

Summary

Previous Close
$0.40
Open
$0.41
Day's Range
$0.39 – $0.42
52 Week Range
$0.34 – $1.60
Volume
40,816
Avg. Volume
198,404
Market Cap
$15.99M
Beta (5Y Monthly)
1.15
PE Ratio (TTM)
--
EPS (TTM)
-$0.21
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$3.00

Profile: Dyadic International, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
5
CEO
Mark A. Emalfarb
Website
dyadic.com

Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$0.03 · Revenue est. $1.43M
DateEst.Actual
Aug 12, 2026-$0.04-$0.06Miss
May 13, 2026-$0.04-$0.05Miss
Mar 25, 2026-$0.03-$0.06Miss
Nov 12, 2025-$0.04-$0.06Miss
Aug 13, 2025-$0.06-$0.06Beat
May 14, 2025–-$0.07

Analyst view

Consensus price target
$3.00 ▲ +651.9%
Range $3.00 – $3.00
Rating: Buy
Buy 50% · Hold 50% · Sell 0%

Get free alerts on DYAI and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.